Alzamend Neuro director granted Series D preferred
Alzamend Neuro director Milton C. Ault III, through Ault Lending, LLC, acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026 as a grant.
Rhea-AI Filing Summary
Alzamend Neuro director Milton C. Ault III, through Ault Lending, LLC, acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026 as a grant. Each share has a stated value of $1,050.00 and is convertible into Common Stock at a variable Conversion Price; as of August 4, 2026, each was convertible into approximately 1,033.5 Common shares. The filing also lists indirect holdings of several Common Stock purchase warrants and direct stock options for 100,000 shares at a $2.33 exercise price expiring in 2035.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series D Convertible Preferred Stock F1, F2, F3, F4 | 7,500 | $1,000.00 | $7.50M |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Common Stock Purchase Warrants F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
Footnotes (5)
- F1. Each share of Series D Convertible Preferred Stock has a stated value of $1,050.00 and is convertible into shares of Common Stock at a conversion price equal to the greater of (i) $0.2668 and (ii) 80% of the lowest closing bid price of the Common Stock during the five (5) trading days immediately prior to the date of conversion into conversion shares, but not greater than $2.00 per share (the "Conversion Price"). The Conversion Price is subject to adjustment in the event of issuances of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.
- F2. The Series D Convertible Preferred Stock has no expiration date.
- F3. As of August 4, 2026, the Conversion Price was $1.016 per share, so each share of Series D Convertible Preferred Stock is convertible into approximately 1,033.5 shares of Common Stock.
- F4. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- F5. On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Ault to purchase 100,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.
Key Figures
Key Terms
Series D Convertible Preferred Stock financial
Conversion Price financial
Common Stock Purchase Warrants financial
vest financial
Section 16 of the Exchange Act regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Milton C. Ault III report in his ALZN Form 4 filing?
What are the conversion terms of ALZN's Series D Convertible Preferred Stock?
What warrants linked to ALZN Common Stock are disclosed in this Form 4?
What stock options in ALZN does Milton C. Ault III hold according to this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.